|
|
Blood, Vol. 111, Issue 3, 1413-1419, February 1, 2008
An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression
Blood Marques et al.
111: 1413
Supplemental materials for: Marques et al
Files in this Data Supplement:
- Figure S1 (JPG, 79.7 KB)
-
(A) Indirect immunofluorescence and flow cytometry to detect HLA-A*0201 expression of cA2Kb-control MEF (red histogram) and cA2Kb-Cdc42 MEF (green histogram). The grey histogram represents the isotype negative control. (B) 5 hour 51Cr release assay of cA2Kb-Cdc42 or cA2Kb-control MEF coincubated with allo A2 CTL (E:T = 30) following pretreatment with PD98059 (closed bars) or vehicle (open bars); mean values + SD. (C) Growth of cA2Kb-control (boxes) and cA2Kb-Cdc42 (circles) fibrosarcomas in NOD/SCID mice. Mice received daily intraperitoneal injections of PD98059 (5 mg/kg; closed symbols) or vehicle (open symbols). Mean values ± SE of bidimensional tumor sizes of five mice per group. (D) Following serum starvation for 12 hours, HCT116-Cdc42 (C) and HCT116-vector (V) colorectal cancer cells were treated with epidermal growth factor (EGF, BD Biosciences, 100 pmol/ml). Cell extracts were obtained at different time points and were analyzed by immunoblotting using the indicated primary antibodies.
| |
